Skip to main content

Table 8 Overall agreement of sample results for the Enzygnost, Novagnost, and Merifluor assays with the established EBV status, including 95% confidence intervals (95% CI)

From: Reliability of the Siemens Enzygnost and Novagnost Epstein–Barr Virus assays for routine laboratory diagnosis: agreement with clinical diagnosis and comparison with the Merifluor Epstein–Barr Virus immunofluorescence assay

  % agreement with established EBV status
  Negative (N = 39) Acute infection (N = 15) Past infection (N = 464)
[95% CI] [95% CI] [95% CI]
Enzygnost 100 100 99.1
[90.97% – 100%] [78.2% – 100%] [97.81% – 99.75%]
Novagnost 89.7 100 86a, 98.8b
[75.78% – 97.13%] [78.2% – 100%] [82.5% – 89.02%]a, [97.1% to 99.6%]b
Merifluor IFA 92.3 100 98.1
[79.13% – 98.38%] [78.2% – 100%] [96.35% – 99.11%]
  1. a Agreement if all indeterminate results are included in the analysis.
  2. b Agreement if all indeterminate results are excluded from the analysis.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us